Department of Traditional Chinese Medicine/ Integrative Oncology, established in 1956, is one of the earliest departments specializing in integrative oncology in China. Over years of development, the department is currently a National Key Clinical Specialty on Integrative Oncology for medical treatment, teaching and research. 
The department is composed of 19 staff, including 4 professors and 7 associate professors, among which 4 are PhD candidate supervisor and 4 are Master candidate supervisor. The honorary professor of the department, Prof. Erxin Yu holds a National Famous doctor title. Prof. Luming Liu, acts as vice-presidents in the Committee of Traditional Chinese medicine, Chinese Anti-Cancer Association (CACA). Prof. Zhiqiang Meng serves as the president of the committee of minimally invasive therapy, Shanghai Anti-Cancer Association. During the past decade, a total of 20 PhD candidates and 25 Master candidates graduated from the department, cultivated a large number of talents of Traditional Chinese Medicine/ Integrative oncology in China.
Since 1960, the Department of Traditional Chinese Medicine/ Integrative Oncology has been focusing on the treatment of liver and pancreatic cancer with an integration of Chinese medicine and western medication. Minimally invasive treatment modalities performed in the department includes radiofrequency ablation, cryoablation, high intensity focused ultrasound (HIFU), transcatheter arterial chemoembolization (TACE). With over 130,000 outpatient visits and 3000 inpatients annually, the department has achieved significant therapeutic efficacy in areas of liver and pancreatic cancer, among which the clinical efficacy of HIFU treatment for pancreatic cancer has reached advanced level internationally.
   The department is actively engaged in research in integrative oncology. During the past 5 years, the number of researches and publications has increased progressively. 34 research projects conducted, including NIH/NCI U19 and R01 programs and 12 national natural science foundations of china (NSFC). A total of 30,000,000 RMB funds obtained and 4 patents licensed. 42 research articles were published in the international peer-reviewed journals including Gastroenterology, Onceogen, Mol Oncol, Cancer, Eur J Cancer,  Brit J Cancer, Autophagy, Carcinogenesis, etc. Since 2003, the department has established an International Center of Integrative Oncology (ICIO) and actively collaborated with M.D. Anderson Cancer Center (MDACC). We have received 6 funds including R21, U19 and R01 from US NIH and Chinese Ministry of science and technology. The department is now well known internationally for researches related to invasion and metastasis, therapy response and prognosis predictive markers and natural products in liver and pancreatic cancer.